Alnylam Pharmaceuticals, Inc. Share | Buy US Stock from India on Kuvera

Q: Can I buy Alnylam Pharmaceuticals, Inc. shares in India?

<div>Kuvera makes it super convenient to trade in US Stocks from India. You can buy / sell Alnylam Pharmaceuticals, Inc. stocks after a simple registration process. </div>

Q: How to buy Alnylam Pharmaceuticals, Inc. shares in India?

<div> To buy Alnylam Pharmaceuticals, Inc. shares from India, just follow these simple steps: <div>Step 1: Login to the Kuvera app or website and go to US Stocks.</div> <div>Step 2: Link your existing Vested US investing account, or create a new one.</div> <div>Step 3: Complete all the KYC process and fund your US Stock trading account.</div> <div>Step 4: Place buy order for Alnylam Pharmaceuticals, Inc. and you are done!</div> </div>

Q: What is the share price of Alnylam Pharmaceuticals, Inc.?

<div>The share price of Alnylam Pharmaceuticals, Inc. is USD 150.31 as on 2 May.</div>

Q: What is the Market Capitalization of Alnylam Pharmaceuticals, Inc.?

<div>Market capitalization or market cap in short, is the total value of all the stocks of a particular company. Market capitalization of Alnylam Pharmaceuticals, Inc. is USD 18.93B as on 2 May.</div>

Q: What is the PE ratio of Alnylam Pharmaceuticals, Inc.?

<div> The price-to-earnings ratio (P/E ratio) in case of stocks of a company is the ratio between its current share price relative to its earnings per share (EPS). A high P/E ratio indicates that the stock is overvalued in relation to the earnings (revenue) generated. PE ratio of Alnylam Pharmaceuticals, Inc. is -42.90 as on 2 May. </div>

Q: Is Alnylam Pharmaceuticals, Inc. a good stock to buy?

<div>Kuvera provides relevant fundamental details of Alnylam Pharmaceuticals, Inc. to help you evaluate. We also recommend you do thorough research before making an investment decision.</div>

Q: In which sector / industry does Alnylam Pharmaceuticals, Inc. operate?

<div> Alnylam Pharmaceuticals, Inc. operates in Healthcare / Biotechnology

Healthcare Biotechnology

$150.31

+0.34

(2 May)

Loading Chart

Previous close

$150.31

Open

$150.31

Today’s high

$153.85

Today’s low

$147.28

52W low

$141.98

52W high

$218.88

-24.42%

12.72%

-42.90

EPS (TTM)

-3.52

Shares O/S

125.95M

Market cap

18.93B

Insights

ALNY price is above its 200 day moving average

ALNY PE is in the top end of its range over the past 2 years

In beta. Send feedback here.

Compare with other stock

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells.

Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity. .

FAQs

Can I buy Alnylam Pharmaceuticals, Inc. shares in India?

How to buy Alnylam Pharmaceuticals, Inc. shares in India?

What is the share price of Alnylam Pharmaceuticals, Inc.?

What is the Market Capitalization of Alnylam Pharmaceuticals, Inc.?

What is the PE ratio of Alnylam Pharmaceuticals, Inc.?

Is Alnylam Pharmaceuticals, Inc. a good stock to buy?

In which sector / industry does Alnylam Pharmaceuticals, Inc. operate?